Neo-Concept International Group Holdings Ltd approved a share consolidation at their October 29, 2026 EGM, consolidating every 8 shares into 1. This consolidation will reduce the total shares from about 8.48 million to approximately 1.06 million, effective November 10, 2026, on the Nasdaq Capital Market under the symbol "NCI". The move aims to streamline the share structure and may improve trading liquidity. The board also received authority to conduct further consolidations up to a 500-to-1 ratio over the next two years.
Neo-Concept International's share consolidation is noted here alongside market data for context. For readers following the Consumer Cyclical sector, 98 of 134 stocks rose on Pluang as of Nov 02, 2026 20:13 WIB. Marriott International Inc (MAR) gained 5.25% to USD 420.26, Xpeng Inc (XPEV) rose 4.76% to USD 9.47, and Rivian Automotive (RIVN) increased 4.61% to USD 12.72.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
